Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
PRNewswire - November 17, 2005
The vaccine candidate uses the Adenovirus-35 vector technology and expresses HIV-1 antigens. Building on Transgene's viral vectors manufacturing processes and long experience in the field, two vaccine batches and related pharmaceutical intermediates will be produced in Transgene's manufacturing facility located near Strasbourg, France. Under the terms of this 18-month contract, financial details are to remain confidential.
Transgene and IAVI have worked together on two additional projects over the past three years - the manufacturing of several MVA (Modified Vaccinia Ankara) constructs including SIV (Simian Immunodeficiency Virus) genes and a study on the characterization of another vaccine candidate.
"We are very pleased to have been awarded this new manufacturing contract by such a renowned organization in the AIDS field," said Philippe Archinard, Chief Executive Officer of Transgene. "It validates the quality of our manufacturing technology platform and competencies and will contribute to building our revenue stream over 2006 and 2007."
About Transgene
Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has three compounds in Phase II trials and one compound in Phase I studies. Transgene has bio-manufacturing production capacities for viral-based vectors and technologies available for out-licensing. For further information about Transgene, please visit http://www.transgene.fr.
About IAVI
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization working to accelerate the development of safe, effective, preventive AIDS vaccines for the world. Founded in 1996 and operational in 23 countries, the organization manages a portfolio of research and development (R&D) projects, prioritizing vaccine concepts and candidates based on the latest scientific findings. IAVI, based in New York with regional offices in Kenya and India, also is registered as a foundation (Stichting IAVI) under Dutch law and has an office in Amsterdam to oversee its extensive European Program activities. http://www.iavi.org
Forward looking statement:
This press release contains forward-looking statements regarding Transgene's contract manufacturing activities and the related revenues. These statements are based on Transgene's current expectations and beliefs. As is the case with the production of any highly advanced biopharmaceutical products, technical difficulties may arise which cause delays or unanticipated costs. Actual results may therefore be less favorable than anticipated. For a description of the risks facing Transgene, see Transgene's Annual Report on Form 20-F and its other reports on file with the U.S. Securities and Exchange Commission.
(Eurolist Paris: FR0005175080)
SOURCE Transgene S.A.
051117
PR051136
Copyright © 2005 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .